The European Commission (EC) has granted registration approval to Sandoz, a Switzerland-headquartered pharmaceutical company (SWX: SDZ), for its biosimilars Wyost and Jubbonti. These products are reference treatments for Amgen’s (NASDAQ: AMGN) bone treatments Xgeva (denosumab) and Prolia (denosumab), respectively. Sandoz anticipates launching the biosimilars in November 2025.
Wyost is indicated for the treatment of unresectable giant cell tumor of bone and for the prevention of skeletal-related events in patients with advanced malignancies involving bone. Jubbonti is approved for treating osteoporosis in postmenopausal women and in men who are at an increased risk of fractures or bone loss.
According to the public data, Wyost and Jubbonti received approval in the U.S. market earlier this year.- Flcube.com
